ACC 2021 | Emergent CABG for acute MI: Benefits Despite Risk

The latest figures show a lower number of emergency CABG for acute MI, and in turn increased primary PCI. 

ACC 2021 | Cirugía de emergencia en el infarto: beneficios a pesar del alto riesgo

The combination of surgeons not willing to take risks and interventional cardiologists empowered to treat practically any lesion has resulted in fewer patients receiving emergency CABG. Only a few years ago, interventional cardiologists at least had the “courtesy” to agree on a treatment strategy with the surgeon on call. Several years of choosing PCI over CABG have granted interventionists clearance to bypass surgeons and directly proceed to percutaneous intervention, practically in every center. 

This study presented today at ACC 2021 simultaneously published in JAHA, shows the figures behind the above statements. Comparing the years 2000 and 2017, emergency CABG saw a 90% reduction. 

It is also clear that surgical techniques and post operatory care have improved in the same period. This has contributed to keep a clear benefit in terms of mortality, despite volume reduction and case selection. 

When comparing patients undergoing surgery in the first part of the study vs the second part, some interesting information becomes clear


Read also: ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery.


Patients treated in the second, most recent period, were more frequently non-STEMI cases (80.5% vs 56.1%), more often presented non-cardiac multiorgan failure (26.1% vs 8.4%), presented cardiogenic shock (11.5% vs 6.4%) and received mechanical circulatory support (19.8% vs 18.7%; p< 0.001 for all comparisons). 

Despite all the above mentioned, mortality in these periods resulted similar (5.3% in 2000 vs 3.6% in 2017).

Original Title: Temporal trends, clinical characteristics and outcomes of emergent coronary artery bypass grafting for acute myocardial infarction in the United States.

Reference: Patlolla SH et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en J Am Heart Assoc.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...